Download Sample
Add to CartDiabetic Macular Edema Market
By Diagnosis;
Fluorescein Angiography, Fundus Imaging, Optical Coherence Tomography (OCT), and OthersBy Product Type;
Intravitreal Injections and Intravitreal ImplantsBy Therapy Type;
Anti-VEGF, Corticosteroids, and Other Off-label Drugs [Triamcinolone]By Distribution Channel;
Hospital Pharmacy, Retail Pharmacy, and OthersBy End User;
Hospitals, Specialty Clinics, Homecare, and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Diabetic Macular Edema Market Overview
Diabetic Macular Edema Market (USD Million)
Diabetic Macular Edema Market was valued at USD 3,764.74 million in the year 2024. The size of this market is expected to increase to USD 4,236.25 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 1.7%.
Diabetic Macular Edema Market
*Market size in USD million
CAGR 1.7 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 1.7 % |
| Market Size (2024) | USD 3,764.74 Million |
| Market Size (2031) | USD 4,236.25 Million |
| Market Concentration | High |
| Report Pages | 307 |
Major Players
- Regeneron Pharmaceuticals, Inc.
- Novartis AG
- Genentech, Inc. (Roche)
- Allergan plc (AbbVie)
- Bayer AG
- Santen Pharmaceutical Co., Ltd.
- Alimera Sciences, Inc.
- Kodiak Sciences Inc.
- Clearside Biomedical, Inc.
- Oxurion NV
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Diabetic Macular Edema Market
Fragmented - Highly competitive market without dominant players
The Diabetic Macular Edema Market is expanding rapidly, driven by the growing burden of diabetes worldwide. Nearly 35% of individuals with diabetes develop diabetic retinopathy, with about 10% progressing to DME. This increasing patient pool is intensifying demand for treatments that preserve vision and prevent disease progression.
Innovation in Anti-VEGF Treatments
Innovative anti-VEGF therapies are revolutionizing the DME treatment landscape, showing visual improvement in over 60% of cases. Newer long-acting formulations are improving patient compliance and outcomes. These therapies remain a cornerstone of clinical practice and a key growth driver for the market.
Surge in Early Detection Through Screening
Enhanced public awareness and routine screenings have led to early identification of DME in 40% of cases. Early diagnosis enables timely intervention, which not only improves vision outcomes but also increases the effectiveness of existing therapies, further boosting demand for treatment options.
AI and Imaging Technologies Transforming Diagnosis
The integration of AI-enabled retinal imaging and OCT technology has significantly improved DME diagnosis accuracy. More than 50% of current diagnostics utilize these advanced systems, streamlining clinical workflows and supporting individualized treatment planning that aligns with patient needs.
Diabetic Macular Edema Market Recent Developments
-
In March 2022, Novartis had announced the approval of the European Commission (EC) Beovu (brolucizumab) 6 mg. it is used for treating visual impairment which occurs due to diabetic macular edema (DME). Year one data from the Phase III KESTREL and KITE studies, which compared Beovu (brolucizumab) 6 mg to aflibercept 2 mg in DME patients, were used to gain approval. Beovu was non-inferior to aflibercept in terms of change in best-corrected visual acuity (BCVA) from baseline in KESTREL and KITE, and showed promise for fluid resolution in numerically more DME patients than aflibercept.
-
In March 2022, the European Commission granted approval for Novartis' BEOVU (brolucizumab) at a dosage of 6 mg to treat visual impairment caused by diabetic macular edema (DME). This marks the drug's second indication, having first been authorized for use in wet age-related macular degeneration in 2020.
Diabetic Macular Edema Market Segment Analysis
In this report, the Diabetic Macular Edema Market has been segmented by Diagnosis, Product Type, Therapy Type, Distribution Channel, End User, and Geography.
Diabetic Macular Edema Market, Segmentation by Diagnosis
The Diabetic Macular Edema Market has been segmented by Fluorescein Angiography, Fundus Imaging, Optical Coherence Tomography (OCT), and Others
Fluorescein Angiography
Fluorescein angiography leads the market with nearly 35% share, serving as a critical tool for visualizing retinal blood vessels in diabetic macular edema. It helps detect leakages and abnormalities with high accuracy. Its continued use in clinical diagnostics drives steady demand.
Fundus Imaging
Fundus imaging accounts for about 25% of the market, valued for its non-invasive approach in capturing detailed retinal images. This method supports early detection and monitoring of diabetic eye conditions. Growing adoption in routine screenings supports consistent growth.
Optical Coherence Tomography (OCT)
Optical coherence tomography (OCT) represents around 30% of the market, recognized for providing high-resolution cross-sectional images of the retina. OCT enables precise measurement of macular thickness, making it vital for treatment planning. Its advanced capabilities ensure strong adoption in this field.
Others
The ‘Others’ category holds close to 10% of the market, covering emerging imaging and diagnostic technologies. These tools offer alternative methods for evaluating diabetic macular edema. Ongoing innovation in this segment supports gradual but steady expansion.
Diabetic Macular Edema Market, Segmentation by Product Type
The Diabetic Macular Edema Market has been segmented by Product Type into Intravitreal Injections and Intravitreal Implants.
Intravitreal Injections
Intravitreal injections dominate the market with nearly 70% share, widely used for delivering anti-VEGF therapies and corticosteroids directly into the eye. Their effectiveness in reducing swelling and preserving vision makes them the preferred treatment method. Growing clinical use ensures sustained demand for this segment.
Intravitreal Implants
Intravitreal implants account for about 30% of the market, offering a long-term drug delivery solution for diabetic macular edema. These implants provide a controlled release of medication, reducing the need for frequent injections. Their convenience and extended efficacy support increasing adoption in this category.
Diabetic Macular Edema Market, Segmentation by Therapy Type
The Diabetic Macular Edema Market has been segmented by Therapy Type into Anti-VEGF, Corticosteroids, and Other Off-label Drugs[Triamcinolone].
Anti-VEGF
Anti-VEGF therapy dominates the market with nearly 65% share, as it is the gold standard for treating diabetic macular edema. These treatments reduce abnormal blood vessel growth and swelling in the retina, improving vision outcomes. Strong clinical evidence supports ongoing adoption worldwide.
Corticosteroids
Corticosteroids account for about 25% of the market, valued for their anti-inflammatory properties in managing retinal swelling. They are particularly useful in patients unresponsive to anti-VEGF therapies. Sustained-release formulations are driving steady growth in this segment.
Other Off-label Drugs [Triamcinolone]
Other off-label drugs, including triamcinolone, hold around 10% of the market, providing alternative options for select patients. These therapies are used in cases requiring customized treatment approaches. Continued research into off-label use supports gradual expansion of this category.
Diabetic Macular Edema Market, Segmentation by Distribution Channel
The Diabetic Macular Edema Market has been segmented by Distribution Channel into Hospital Pharmacy, Retail Pharmacy, and Others.
Hospital Pharmacy
Hospital pharmacies dominate the market with nearly 55% share, as most intravitreal treatments and therapies for diabetic macular edema are administered in hospitals. They ensure timely access to specialized medications under strict supervision. Their critical role supports consistent demand in this channel.
Retail Pharmacy
Retail pharmacies account for about 30% of the market, offering easier accessibility to supportive drugs and prescriptions. Patients rely on these outlets for convenient refills and follow-up medications. Expanding networks of retail pharmacies contribute to steady growth in this segment.
Others
The ‘Others’ category represents around 15% of the market, including online pharmacies and specialty distributors. These channels provide alternative supply options and reach underserved areas. Increasing reliance on digital platforms fuels gradual expansion of this distribution channel.
Diabetic Macular Edema Market, Segmentation by End User
The Diabetic Macular Edema Market has been segmented by Hospitals, Specialty Clinics, Homecare, and Others
Hospitals
Hospitals lead the diabetic macular edema market with nearly 50% share, serving as the primary centers for advanced eye treatments and surgeries. They provide access to intravitreal injections, implants, and specialized diagnostics. Their comprehensive infrastructure ensures sustained demand in this segment.
Specialty Clinics
Specialty clinics account for about 30% of the market, focusing on targeted ophthalmology care for diabetic patients. These facilities offer personalized treatment plans and advanced therapies. Growing awareness of specialist care supports steady adoption in this category.
Homecare
Homecare contributes around 10% of the market, driven by the rise of remote monitoring tools and supportive care products. Patients benefit from easier access to follow-up treatments and ongoing assistance. Expanding home-based solutions fuels increasing interest in this segment.
Others
The ‘Others’ category holds roughly 10% of the market, including research institutes and community health centers. These entities play a role in pilot programs, clinical studies, and outreach initiatives. Their contributions ensure continued growth in this segment.
Global Diabetic Macular Edema Market, Segmentation by Geography
In this report, the Global Diabetic Macular Edema Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
Regions and Countries Analyzed in this Report
Diabetic Macular Edema Market Share (%), by Geographical Region
North America
North America leads the diabetic macular edema market with nearly 42% share, driven by advanced healthcare infrastructure and widespread availability of intravitreal therapies. The strong presence of key manufacturers and research facilities continues to support innovation. Rising prevalence of diabetes ensures ongoing demand in this region.
Europe
Europe accounts for about 30% of the market, supported by robust screening programs and access to cutting-edge ophthalmology treatments. Well-established clinical networks and growing focus on early diagnosis enhance market performance. Consistent adoption across multiple countries drives steady growth.
Asia Pacific
Asia Pacific holds nearly 18% of the market, fueled by rising diabetes rates and improving access to ophthalmic care. Countries like China, Japan, and India are investing in advanced diagnostic tools and treatment infrastructure. Rapid healthcare development supports strong momentum for this region.
Middle East & Africa
Middle East & Africa represent close to 6% of the market, showing gradual growth from emerging healthcare systems and awareness programs. Expanding availability of specialized eye care services supports adoption. Continued investments in infrastructure drive further expansion.
Latin America
Latin America contributes roughly 4% of the market, with Brazil and Mexico leading in ophthalmology treatments. Increasing access to intravitreal injections and public health initiatives support market presence. Efforts to improve awareness and treatment options sustain steady demand.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Diabetic Macular Edema Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers :
- Increasing Prevalence of Diabetes
- Advancements in Medical Technology
-
Growing Awareness and Screening Programs : Growing awareness about the complications associated with diabetes and the critical importance of early diagnosis are key factors driving the diabetic macular edema (DME) market. As educational campaigns and public health initiatives highlight the risks and symptoms of DME, more patients and healthcare providers are vigilant in monitoring eye health in diabetic individuals. This heightened awareness ensures that more patients seek timely medical advice, reducing the progression of DME and improving treatment outcomes. The proactive stance on eye health, supported by extensive information dissemination, helps in recognizing DME at its nascent stages, making interventions more effective.
Governments and healthcare organizations are playing a pivotal role by implementing comprehensive screening programs, especially in regions with high diabetes prevalence. These programs aim to systematically identify and monitor individuals at risk, facilitating early detection and prompt treatment of DME. By incorporating regular eye examinations into diabetes management protocols, these initiatives ensure that more cases are diagnosed before severe complications arise. The emphasis on early detection not only enhances patient prognosis but also underscores the importance of integrated healthcare approaches in managing chronic conditions like diabetes.
Restraints :
- High Treatment Costs
- Side Effects and Complications
-
Lack of Infrastructure in Developing Regions : In developing and underdeveloped regions, the inadequate healthcare infrastructure poses a significant barrier to the effective diagnosis and treatment of diabetic macular edema (DME). Many of these areas suffer from a shortage of essential medical facilities and diagnostic tools, which are critical for the early detection and management of DME. The lack of specialized equipment and up-to-date technology hampers the ability to provide timely and accurate diagnoses, leading to delayed or missed treatments. This infrastructure deficit makes it challenging to implement comprehensive care strategies, leaving many patients without the necessary medical attention.
The shortage of trained medical professionals exacerbates the problem. In these regions, there is often a limited number of healthcare providers with the expertise to manage and treat complex conditions like DME. This scarcity of skilled personnel results in suboptimal care and limits the capacity to deliver advanced treatment options, such as anti-VEGF therapies or laser treatments. Consequently, the overall growth of the DME market in these areas is significantly restricted, as both patients and healthcare systems struggle to cope with the demands of effective diabetes-related eye care.
Opportunities :
- Emerging Markets
- Development of Novel Therapies
-
Telemedicine and Remote Monitoring : The adoption of telemedicine and remote patient monitoring solutions offers significant growth opportunities for the diabetic macular edema (DME) market. These technologies enhance patient access to care, especially in remote or underserved areas where traditional healthcare services may be limited. Telemedicine allows patients to consult with specialists without the need for extensive travel, facilitating timely and convenient medical advice. This accessibility is crucial for the early detection and ongoing management of DME, as it enables continuous monitoring and swift intervention when necessary. By bridging geographical barriers, telemedicine ensures that more patients receive appropriate and consistent care.
Remote patient monitoring further complements this by providing real-time data on patients' health status, enabling proactive management of diabetes and its complications. Devices and applications that track blood sugar levels, blood pressure, and other relevant metrics allow healthcare providers to monitor patients continuously and make informed decisions promptly. This continuous oversight helps in the early identification of potential issues, reducing the risk of severe DME progression. Together, telemedicine and remote monitoring create a more integrated and responsive healthcare system, improving patient outcomes and driving market growth by making advanced care more accessible and efficient.
Competitive Landscape Analysis
Key players in Global Diabetic Macular Edema Market include
- Regeneron Pharmaceuticals, Inc.
- Novartis AG
- Genentech, Inc. (Roche)
- Allergan plc (AbbVie)
- Bayer AG
- Santen Pharmaceutical Co., Ltd.
- Alimera Sciences, Inc.
- Kodiak Sciences Inc.
- Clearside Biomedical, Inc.
- Oxurion NV
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Diagnosis
- Market Snapshot, By Product Type
- Market Snapshot, By Therapy Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By End User
- Market Snapshot, By Region
- Diabetic Macular Edema Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Prevalence of Diabetes
- Advancements in Medical Technology
- Growing Awareness and Screening Programs
- Restraints
- High Treatment Costs
- Side Effects and Complications
- Lack of Infrastructure in Developing Regions
- Opportunities
- Emerging Markets
- Development of Novel Therapies
- Telemedicine and Remote Monitoring
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Diabetic Macular Edema Market, By Diagnosis, 2021 - 2031 (USD Million)
- Fluorescein Angiography
- Fundus Imaging
- Optical Coherence Tomography (OCT)
- Others
- Diabetic Macular Edema Market,By Product Type, 2021 - 2031 (USD Million)
- Intravitreal Injections
- Intravitreal Implants
- Diabetic Macular Edema Market, By Therapy Type, 2021 - 2031 (USD Million)
- Anti-VEGF
- Corticosteroids
- Other Off-label Drugs
- Triamcinolone
- Diabetic Macular Edema Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacy
- Retail Pharmacy
- Others
- Diabetic Macular Edema Market, By End User, 2021 - 2031 (USD Million)
- Hospitals
- Specialty Clinics
- Homecare
- Others
- Diabetic Macular Edema Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Diabetic Macular Edema Market, By Diagnosis, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Regeneron Pharmaceuticals, Inc.
- Novartis AG
- Genentech, Inc. (Roche)
- Allergan plc (AbbVie)
- Bayer AG
- Santen Pharmaceutical Co., Ltd.
- Alimera Sciences, Inc.
- Kodiak Sciences Inc.
- Clearside Biomedical, Inc.
- Oxurion NV
- Company Profiles
- Analyst Views
- Future Outlook of the Market